# Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease

> **NCT04311112** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Retinagenix Holdings**

## Conditions studied

- Retinal Disorder

## Interventions

- **DRUG:** Placebos
- **DRUG:** ZA Low dose
- **DRUG:** ZA high dose

## Key facts

- **NCT ID:** NCT04311112
- **Lead sponsor:** Retinagenix Holdings
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2023-02
- **Final completion:** 2023-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The asset was transferred to another company
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311112, "Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04311112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*